

Truly Labs AB include Lumito's tissue analysis technology into its customer offering

Lumito AB (publ) ("Lumito" or the "Company") today announces that Truly Labs AB ("Truly Labs"), following an evaluation period, has decided to include SCIZYS, Lumito's product for advanced tissue analysis, in its service offering to research and pharmaceutical clients.

The decision follows the pilot study jointly conducted by Lumito and Truly Labs earlier this year. The results, communicated in Lumito's press release on 28 August 2025, demonstrated that the SCIZYS platform can generate more information from each tissue sample and enable more precise analyses compared to traditional methods.

After completing its evaluation, Truly Labs concluded that SCIZYS adds significant value – both by improving the quality of existing analyses and by enabling new types of studies.

"We see that Lumito's SCIZYS platform strengthens our ability to deliver even more detailed and reliable results to our customers. The combination of high sensitivity, precise localisation, and wide dynamic range provides us with new tools to deepen our understanding of biological processes and further enhance our analyses," commented Karin von Wachenfeldt, CEO of Truly Labs.

Lumito's SCIZYS platform is based on the Company's unique use of upconverted nanoparticles (UCNPs) as a light source, which eliminates background interference and enables high-contrast imaging with exceptional detail.

"We are very pleased that Truly Labs has chosen to integrate Lumito's technology into its offering. This confirms the relevance and potential of our technology to create concrete value in research environments where data quality and precision are key," commented Sanna Wallenborg, CEO of Lumito.

The collaboration between Lumito and Truly Labs, which began in December 2024, has developed step by step, and Truly Labs' decision to integrate the technology into its customer offering marks an important milestone in Lumito's strategy to establish SCIZYS as a valuable platform within preclinical research and drug development.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

About Truly Labs

Truly Labs AB is a Contract Research Organization (CRO) providing customized in vitro and in vivo services to its customers. Truly Labs was founded in January 2015 as a subsidiary of Truly Translational AB. The Truly Labs' team has a solid track record with scientific and experimental expertise and experience from drug research & development in both large pharma and biotech, and extensive experience of working with both small molecules and biologics. Truly Labs' key therapeutic areas are inflammation, respiratory diseases, oncology and autoimmune diseases where we offer state of the art in vitro and in vivo technologies. www.trulytranslational.com

Attachments

[Truly Labs AB include Lumito's tissue analysis technology into its customer offering](#)